Every day, our scientists seek to identify "good research seeds" that can be developed into high quality pharmaceuticals. These "seeds" are identified in Shionogi labs as well as in collaboration or partnership with other companies. From these seeds, Shionogi works to cultivate major global brands.
Our robust pipeline is focused on the needs of a dynamic and rapidly aging society and includes treatments for infection, pain (cancer pain and chronic pain), women’s health, allergic rhinitis, cancer and HIV.
Pain and its associated management (palliative care) is one of the most common medical issues. Naldemedine (S-297995) is an opioid receptor antagonist in late- stage clinical development for the treatment of constipation that results from opioid use. Opioid-induced constipation (OIC) has been estimated to occur in from 15% to 90% of chronic opioid users.1
According to the World Health Organization, antibiotic resistance has emerged as one of the most critical public health concerns of the 21st century2. Shionogi has commenced a series of initiatives to help address antibiotic resistance. The most advanced product in this program is S-649266, a novel parenteral siderophore cephalosporin antibiotic designed to treat gram- negative pathogens including multidrug resistant (MDR) strains.
- Boswell K, Kwong WJ, Kavanagh S. Burden of opioid-associated gastrointestinal side effects from clinical and economic perspectives: a systematic literature review. J Opioid Manag. 2010 Jul-Aug;6(4):269-89. Accessed December 16, 2014
- WHO's first global report on antibiotic resistance reveals serious, worldwide threat to public health. Accessed September 25, 2014